Skip to main content

10x Genomics, Inc.

For the period ended Dec 31, 2025. Filed Feb 13, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 13, 2026

TXG$65.05+9.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

10x Genomics, Inc.
Date: February 12, 2026By:/s/ Serge Saxonov
Serge SaxonovChief Executive Officer and Director(Principal Executive Officer)

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Serge Saxonov and Adam S. Taich, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Serge SaxonovChief Executive Officer and DirectorFebruary 12, 2026
Serge Saxonov(Principal Executive Officer)
/s/ Benjamin J. HindsonPresident and DirectorFebruary 12, 2026
Benjamin J. Hindson
/s/ Adam S. TaichChief Financial OfficerFebruary 12, 2026
Adam S. Taich(Principal Accounting and Financial Officer)
/s/ John R. StuelpnagelChairman of the Board of DirectorsFebruary 12, 2026
John R. Stuelpnagel
/s/ Sridhar KosarajuDirectorFebruary 12, 2026
Sridhar Kosaraju
/s/ Alan MateoDirectorFebruary 12, 2026
Alan Mateo
/s/ Kim PopovitsDirectorFebruary 12, 2026
Kim Popovits
/s/ Shehnaaz SulimanDirectorFebruary 12, 2026
Shehnaaz Suliman
/s/ Sarah TeichmannDirectorFebruary 12, 2025
Sarah Teichmann
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.